Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of lazertinib plus subcutaneous amivantamab versus intravenous amivantamab in EGFR-mutant advanced or metastatic non-small cell lung cancer after progression on osimertinib and platinum chemotherapy
CTR20222664Phase 3Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of lazertinib, amivantamab in non-small cell lung cancer (NSCLC), sponsored by Janssen Pharmaceutical. Started Jan 2023; status: active.
02
Drugs
lazertinibamivantamab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20222664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222664.